Lixte Biotechnology is a clinical-stage biopharmaceutical company developing cancer therapies through two complementary segments: LB-100, a small-molecule inhibitor of protein phosphatase 2A designed to enhance the effectiveness of conventional cancer treatments like chemotherapy, radiation, and immune checkpoint inhibitors by transiently disrupting DNA damage repair; and Liora Technologies, a proton therapy platform developing an electronically controlled linear accelerator system that offers advantages over conventional cyclotron-based systems including reduced infrastructure costs and compatibility with ultra-high-dose-rate therapy. The company currently operates without revenue-generating operations and funds development through equity financing, pursuing a long-term strategy of licensing agreements with major pharmaceutical companies and proton therapy centers. LB-100 holds FDA Investigational New Drug status and is in clinical trials across multiple cancer indications, while the Liora proton therapy system remains a non-clinical prototype requiring further development.